Dexcom G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use During Pregnancy in the EU
February 20 2020 - 3:00AM
Business Wire
Revolutionary CGM system indicated for persons
age 2 years and older, now also includes pregnant women, starting
spring 2020
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose
monitoring (CGM), announced today the Dexcom G6 CGM System has
received the CE Mark for use during pregnancy in the EU, and will
be available soon, starting with the United Kingdom in Spring
2020.
Poorly controlled glucose levels in pregnant women with Type 1,
Type 2 or gestational diabetes can lead to serious problems for the
mother and child, and the solutions for managing diabetes during
pregnancy are currently limited. The CE Mark of the Dexcom G6 for
pregnant women provides more choice for both healthcare
professionals and patients to manage their disease.
“We are excited that the Dexcom G6 has received the CE mark in
the EU for use during pregnancy. It is a life-changing development
for this group of patients and highlights our continued mission to
innovate on behalf of everyone living with diabetes,” said Erik
Bjorkman, Dexcom general manager and vice president for EMEA.
Glucose levels are hard to manage in pregnancy due to the
increasing need for and resistance to insulin. CGM is a means of
measuring glucose levels continuously throughout the day and night
and can provide short-term insight into the effectiveness of
diabetes interventions. With the Dexcom G6 CGM now available for
use during pregnancy, pregnant women living with Type 1, Type 2 or
gestational diabetes can now have their CGM data readily available,
which can help make their diabetes easier to manage.
Furthermore, with the Dexcom G6 app, patients can share their
glucose information with up to five people who have the separate
Dexcom Follow App and an internet connection. This additional
feature enables family and loved ones to remotely monitor patients
for extra peace of mind. It also provides ease of management when
pregnant and sharing health data with your healthcare
professional.
“Women with Type 1 or Type 2 in pregnancy or those with
gestational diabetes usually require six or more fingersticks per
day. These are required during the night, before meals, as well as
after eating meals and snacks,” said Helen Murphy, MD, professor of
medicine at the University of East Anglia in Norwich, U.K. “CGM
eliminates the need for fingersticks and provides patients with
regular updates and alerts throughout the day and night. This
allows them to manage their glucose levels with confidence during
pregnancy and helps them to deliver healthy babies.”
For questions about using the Dexcom G6 during pregnancy, please
consult your healthcare provider. For more information about Dexcom
CGM, visit www.dexcom.com.
About DexCom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, California, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom simplifies and improves
diabetes management around the world. For more information about
Dexcom CGM, visit www.dexcom.com.
© 2020 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are
registered trademarks of Dexcom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200220005035/en/
Dexcom Investor Contact: Steven R. Pacelli, (858)
200-0200 Executive Vice President, Strategy and Corporate
Development
Dexcom Media Contact: James McIntosh, (619) 884-2118
Senior Manager, Public Relations james.mcintosh@dexcom.com
Dexcom UK / EMEA Media Contact: Ellis Mendon, +44 (0) 203
551 7736 dexcomuk@allisonpr.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024